UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mass spectrometry-based discovery of circadian peptides

Proceedings of the National Academy of Sciences - PNAS, 2008-08, Vol.105 (34), p.12527-12532

2008

Volltextzugriff (PDF)

Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines

BMC geriatrics, 2022-06, Vol.22 (1), p.484-484, Article 484

2022

Volltextzugriff (PDF)

Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

The journal of clinical psychiatry, 2021-06, Vol.82 (4)

2021

Volltextzugriff (PDF)

Comparing Label-Free Quantitative Peptidomics Approaches to Characterize Diurnal Variation of Peptides in the Rat Suprachiasmatic Nucleus

Analytical chemistry (Washington), 2014-01, Vol.86 (1), p.443-452

2014

Volltextzugriff (PDF)

Quantitative Peptidomics for Discovery of Circadian-Related Peptides from the Rat Suprachiasmatic Nucleus

Journal of proteome research, 2013-02, Vol.12 (2), p.585-593

2013

Volltextzugriff (PDF)

Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder

Sleep medicine, 2022-02, Vol.90, p.249-257

2022

Volltextzugriff (PDF)

Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study

Advances in therapy, 2022-03, Vol.39 (3), p.1324-1340

2022

Volltextzugriff (PDF)

Circadian integration of glutamatergic signals by little SAAS in novel suprachiasmatic circuits

PloS one, 2010-09, Vol.5 (9), p.e12612-e12612

2010

Volltextzugriff (PDF)

Endogenous peptide discovery of the rat circadian clock: a focused study of the suprachiasmatic nucleus by ultrahigh performance tandem mass spectrometry

Molecular & cellular proteomics, 2010-02, Vol.9 (2), p.285-297

2010

Volltextzugriff (PDF)

Functional Peptidomics: Stimulus- and Time-of-Day-Specific Peptide Release in the Mammalian Circadian Clock

ACS chemical neuroscience, 2018-08, Vol.9 (8), p.2001-2008

2018

Volltextzugriff (PDF)

The Patient Experience with DSM-5-Defined Binge Eating Disorder: Characteristics, Barriers to Treatment, and Implications for Primary Care Physicians

Postgraduate medicine, 2014-09, Vol.126 (5), p.52-63

2014

Volltextzugriff (PDF)

Direct cellular peptidomics of hypothalamic neurons

Frontiers in neuroendocrinology, 2011-10, Vol.32 (4), p.377-386

2011

Volltextzugriff (PDF)

Effect of Lemborexant on Fatigue Severity and Sleep Outcomes Over 12 Months in Subjects With Clinically Significant Fatigue at Baseline (1593)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Effect of Lemborexant on Patient-Reported Distress About Sleeping and Interference with Daily Functioning in Subjects With Insomnia (1582)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

335 Evaluation of Dose Transition From Zolpidem to Lemborexant Across 14 Weeks: Results From a Multicenter Open-label Pilot Study

Sleep (New York, N.Y.), 2021-05, Vol.44 (Supplement_2), p.A134-A134

2021

Volltextzugriff (PDF)

336 Effect of Lemborexant Versus Placebo and Zolpidem on REM Sleep by Quarter Night Intervals in Older Adults with Insomnia Disorder

Sleep (New York, N.Y.), 2021-05, Vol.44 (Supplement_2), p.A134-A134

2021

Volltextzugriff (PDF)

337 A Multicenter Open-label Pilot Study Evaluating Next-Dose Transition From Zolpidem to Lemborexant: Analysis of Female Subgroup

Sleep (New York, N.Y.), 2021-05, Vol.44 (Supplement_2), p.A134-A135

2021

Volltextzugriff (PDF)

Endogenous Peptide Discovery of the Rat Circadian Clock

Molecular & cellular proteomics, 2010-02, Vol.9 (2), p.285-297

2010

Volltextzugriff (PDF)

Assessing Lemborexant Efficacy and Safety in the Treatment of Insomnia

Journal of the National Medical Association, 2020-10, Vol.112 (5), p.S34-S34

2020

Volltextzugriff (PDF)

Impact of Lemborexant Treatment on Insomnia Disease Severity and Fatigue: Results from the 12-Month Phase 3 Study SUNRISE-2 (112)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Establishing US norms for the Adult ADHD Self‐Report Scale (ASRS‐v1.1) and characterising symptom burden among adults with self‐reported ADHD

International journal of clinical practice (Esher), 2019-01, Vol.73 (1), p.e13260-n/a

2019

Volltextzugriff (PDF)

Impact of Lemborexant on Fatigue Severity and Sleep Outcomes in Older Adults With Clinically Significant Fatigue at Baseline

The American journal of geriatric psychiatry, 2021-04, Vol.29 (4), p.S125-S126

2021

Volltextzugriff (PDF)

Efficacy and Safety of Lemborexant in Subjects Previously Randomized to Placebo for 6 Months

Journal of the National Medical Association, 2020-10, Vol.112 (5), p.S27-S27

2020

Volltextzugriff (PDF)

164 Pooled Analyses of Patient-Reported Sleep Onset and Maintenance from Two Phase 3 Studies of Lemborexant

CNS spectrums, 2020-04, Vol.25 (2), p.304-305

2020

Volltextzugriff (PDF)

165 Impact of Lemborexant on Insomnia Disease Severity and Fatigue: Results from the 6-Month Placebo-Controlled Period of the Phase 3 SUNRISE-2 Study

CNS spectrums, 2020-04, Vol.25 (2), p.305-306

2020

Volltextzugriff (PDF)

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(127)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(169)
Deutsch
(2)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(72)
Life Sciences & Biomedicine
(67)
Humans
(55)
Female
(40)
Middle Aged
(32)
Biological And Medical Sciences
(25)
Male
(25)
Medical Sciences
(24)
Adult
(23)
Oncology
(23)
Aged
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Tumors
(18)
Chemotherapy, Adjuvant
(16)
Treatment Outcome
(16)
Animals
(14)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(14)
Breast Neoplasms - Drug Therapy
(14)
Disease-Free Survival
(13)
Chemotherapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mass spectrometry-based discovery of circadian peptides

Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines

Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Comparing Label-Free Quantitative Peptidomics Approaches to Characterize Diurnal Variation of Peptides in the Rat Suprachiasmatic Nucleus

Quantitative Peptidomics for Discovery of Circadian-Related Peptides from the Rat Suprachiasmatic Nucleus

Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder

Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study

Circadian integration of glutamatergic signals by little SAAS in novel suprachiasmatic circuits

Endogenous peptide discovery of the rat circadian clock: a focused study of the suprachiasmatic nucleus by ultrahigh performance tandem mass spectrometry

Functional Peptidomics: Stimulus- and Time-of-Day-Specific Peptide Release in the Mammalian Circadian Clock

The Patient Experience with DSM-5-Defined Binge Eating Disorder: Characteristics, Barriers to Treatment, and Implications for Primary Care Physicians

Direct cellular peptidomics of hypothalamic neurons

Effect of Lemborexant on Fatigue Severity and Sleep Outcomes Over 12 Months in Subjects With Clinically Significant Fatigue at Baseline (1593)

Effect of Lemborexant on Patient-Reported Distress About Sleeping and Interference with Daily Functioning in Subjects With Insomnia (1582)

335 Evaluation of Dose Transition From Zolpidem to Lemborexant Across 14 Weeks: Results From a Multicenter Open-label Pilot Study

336 Effect of Lemborexant Versus Placebo and Zolpidem on REM Sleep by Quarter Night Intervals in Older Adults with Insomnia Disorder

337 A Multicenter Open-label Pilot Study Evaluating Next-Dose Transition From Zolpidem to Lemborexant: Analysis of Female Subgroup

Endogenous Peptide Discovery of the Rat Circadian Clock

Assessing Lemborexant Efficacy and Safety in the Treatment of Insomnia

Impact of Lemborexant Treatment on Insomnia Disease Severity and Fatigue: Results from the 12-Month Phase 3 Study SUNRISE-2 (112)

Establishing US norms for the Adult ADHD Self‐Report Scale (ASRS‐v1.1) and characterising symptom burden among adults with self‐reported ADHD

Impact of Lemborexant on Fatigue Severity and Sleep Outcomes in Older Adults With Clinically Significant Fatigue at Baseline

Efficacy and Safety of Lemborexant in Subjects Previously Randomized to Placebo for 6 Months

164 Pooled Analyses of Patient-Reported Sleep Onset and Maintenance from Two Phase 3 Studies of Lemborexant

165 Impact of Lemborexant on Insomnia Disease Severity and Fatigue: Results from the 6-Month Placebo-Controlled Period of the Phase 3 SUNRISE-2 Study

Suchergebnisse filtern